PhotoCure ASA (FRA:PHS) Beginning Cash Position: €21.40 Mil (As of Mar. 2026)


FRA:PHS PhotoCure ASA FRA:PHS
76 GF Score
Price €5.15
GF Value €6.52
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Beginning Cash Position?

PhotoCure ASA FRA:PHS +2.18% 76 Beginning Cash Position is €21.40 Mil as of Mar. 2026. GuruFocus rates FRA:PHS with a GF Score™ of 76/100 and a GF Value™ of €6.52 (Modestly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA's Beginning Cash Position for the quarter that ended in Mar. 2026 was €21.40 Mil.

PhotoCure ASA's quarterly Beginning Cash Position increased from Sep. 2025 (€20.49 Mil) to Dec. 2025 (€20.94 Mil) and increased from Dec. 2025 (€20.94 Mil) to Mar. 2026 (€21.40 Mil).

PhotoCure ASA's annual Beginning Cash Position declined from Dec. 2023 (€23.30 Mil) to Dec. 2024 (€22.09 Mil) but then increased from Dec. 2024 (€22.09 Mil) to Dec. 2025 (€24.83 Mil).

PhotoCure ASA Beginning Cash Position Related Terms

PhotoCure ASA Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PhotoCure ASA's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Beginning Cash Position Chart

PhotoCure ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.00 30.85 23.30 22.09 24.83

PhotoCure ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.46 22.39 20.49 20.94 21.40
FRA:PHS
76GF Score
PhotoCure ASA FRA:PHS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhotoCure ASA Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €21.40 Mil mean?
PhotoCure ASA (FRA:PHS) has a Beginning Cash Position of €21.40 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PhotoCure ASA and its competitors.
Is PhotoCure ASA's Beginning Cash Position too high?
PhotoCure ASA's current Beginning Cash Position is €21.40 Mil. Overall, PhotoCure ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Beginning Cash Position compare to ZTS and UTHR?
PhotoCure ASA's Beginning Cash Position of €21.40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PhotoCure ASA and its competitors. PhotoCure ASA's current Beginning Cash Position is €21.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.52, compared to a current price of €5.15 — trading 21% below its estimated fair value. The current Beginning Cash Position is €21.40 Mil. PhotoCure ASA's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Beginning Cash Position is €21.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.15 is trading 21% below its estimated GF Value™ of €6.52. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Beginning Cash Position: €21.40 Mil
  • GF Value™: €6.52 vs. price of €5.15 (21% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
76GF Score

Get the complete analysis for FRA:PHS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.15
Price
€6.52
GF Value